Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cell Metab. 2009 Dec;10(6):491-8. doi: 10.1016/j.cmet.2009.09.007.

Prevention of steatosis by hepatic JNK1.

Author information

  • 1Howard Hughes Medical Institute, University of Massachusetts Medical School, Worcester, MA 01605, USA.

Abstract

Nonalcoholic steatosis (fatty liver) is a major cause of liver dysfunction that is associated with insulin resistance and metabolic syndrome. The cJun NH(2)-terminal kinase 1 (JNK1) signaling pathway is implicated in the pathogenesis of hepatic steatosis and drugs that target JNK1 may be useful for treatment of this disease. Indeed, mice with defects in JNK1 expression in adipose tissue are protected against hepatic steatosis. Here we report that mice with specific ablation of Jnk1 in hepatocytes exhibit glucose intolerance, insulin resistance, and hepatic steatosis. JNK1 therefore serves opposing actions in liver and adipose tissue to both promote and prevent hepatic steatosis. This finding has potential implications for the design of JNK1-selective drugs for the treatment of metabolic syndrome.

Comment in

PMID:
19945406
[PubMed - indexed for MEDLINE]
PMCID:
PMC2804105
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk